SEC Company Response from Nuo Therapeutics, Inc. (AURX) (CIK 0001091596) (AURX) — Nov 1, 2010

Nuo Therapeutics, Inc. (AURX) (CIK 0001091596)
Date: Nov. 1, 2010 · CIK: 0001091596 · Accession: 0001144204-10-056659

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-168936

Date

November 3, 2010

Author

Cytomedix

Form

CORRESP

Company

Nuo Therapeutics, Inc. (AURX) (CIK 0001091596)

Letter

Unassociated Document

Cytomedix, Inc.

Perry Parkway, Suite 7, Gaithersburg, MD 20877

November 1, 2010

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

Attn: Mary Beth Breslin, Senior Attorney

Re: Cytomedix, Inc. - Registration Statement on Form S-3 (File No. 333-168936)

Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), Cytomedix, Inc. (the “Company”), respectfully requests that the effective date of its Registration Statement on Form S-3 (File No. 333-168936) (“Registration Statement”) be accelerated and that such Registration Statement become effective at 4:30 P.M., Washington, D.C. time, on November 3, 2010, or as soon thereafter as practicable.

Furthermore, the Company acknowledges the following:

should the Securities and Exchange Commission (“Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

the action of the Commission or the staff, acting pursuant to delegated authority in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

the Company may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very
truly yours,
Cytomedix,
Inc.

Show Raw Text

CORRESP
1
filename1.htm

    Unassociated Document

    Cytomedix,
Inc.

    209
Perry Parkway, Suite 7, Gaithersburg, MD 20877

    November
1, 2010

    Division
of Corporation Finance

    Securities
and Exchange Commission

    100 F
Street, NE

    Washington,
DC 20549

      Attn:
Mary Beth Breslin, Senior Attorney

    Re:           Cytomedix,
Inc. - Registration Statement on Form S-3 (File No. 333-168936)

    Pursuant
to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”),
Cytomedix, Inc. (the “Company”), respectfully requests that the effective date
of its Registration Statement on Form S-3 (File No. 333-168936) (“Registration
Statement”) be accelerated and that such Registration Statement become effective
at 4:30 P.M., Washington, D.C. time, on November 3, 2010, or as soon thereafter
as practicable.

    Furthermore,
the Company acknowledges the following:

              ·

              should
      the Securities and Exchange Commission (“Commission”) or the staff, acting
      pursuant to delegated authority, declare the Registration Statement
      effective, it does not foreclose the Commission from taking any action
      with respect to the Registration
Statement;

              ·

              the
      action of the Commission or the staff, acting pursuant to delegated
      authority in declaring the Registration Statement effective, does not
      relieve the Company from its full responsibility for the adequacy and
      accuracy of the disclosure in the Registration Statement;
    and

              ·

              the
      Company may not assert staff comments and the declaration of effectiveness
      of the Registration Statement as a defense in any proceeding initiated by
      the Commission or any person under the federal securities laws of the
      United States.

              Very
      truly yours,

              Cytomedix,
Inc.

              /s/ Andrew
      S. Maslan

              Name:
      Andrew S. Maslan

              Title:
      Chief Financial Officer

SecProbe.io